18 results about "Mantle-Zone Lymphomas" patented technology

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.

This invention relates to therapies for treating mantle cell lymphoma comprising a cyclin dependent kinase 4 (CDK4) inhibitor or a pharmaceutically acceptable salt thereof, and associated methods of treatment, pharmaceutical compositions, and uses thereof.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structuralor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

The invention discloses a multiplex fluorescence immunohistochemical detection kit for rare lymphoma and application of the multiplex fluorescence immunohistochemical detection kit. The multiplex fluorescence immunohistochemical detection kit for rare lymphoma comprises a primary antibody reagent and a fluorescence staining reagent, the primary antibody reagent is prepared from a rabbit anti-human CD15 monoclonal antibody, a rabbit anti-human CD30 monoclonal antibody, a KI-67 monoclonal antibody, a rabbit anti-human CD79b monoclonal antibody, a rabbit anti-human CD3 monoclonal antibody and a rabbit anti-human CD20 monoclonal antibody. When the multiplex fluorescence immunohistochemical detection kit for the rare lymphoma is used, a false positive result caused by channel spectrum crosstalk is avoided to the greatest extent through a specific staining sequence of each target protein and fluorescein matching, and the purpose of detecting the rare lymphoma, especially the rare type of lymphoma, is achieved. The kit can be used for synchronous detection of lymphoma, such as hodgkin lymphoma, mantle cell lymphoma and marginal region lymphoma, and provides a reliable basis for lymphoma immune targeted therapy.

Provided herein are methods of treating diseases (e.g., proliferative disease (e.g., cancer (e.g., breast cancer, colon cancer, testicular cancer, CNS cancer, stomach cancer, lymphoma (e.g., B-cell lymphoma (e.g., lymphoplasmacytic lymphoma (e.g., IgM secreting lymphoplasmacytic lymphoma (i.e., Waldenstrom's Macroglobulinemia), non-IgM secreting lymphoplasmacytic lymphoma)), diffuse large B-cell lymphoma (e.g., activated B-cell-like (ABC)-DLBCL, germinal center B-cell-like (GBC)-DLBCL), follicular lymphoma, marginal zone B-cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma), and leukemia (e.g., chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, myelogenous leukemia (e.g., chronic myelogenous leukemia, acute myelogenous leukemia))))) comprising administering to the subject in need thereof a therapeutically effective amount of Compound (I). Further provided are methods for treating disease resistant to treatment with BTK inhibitors (e.g., ibmtinib). Formula (I)

Disclosed in the present application are compounds having a benzamide structure as shown in formula (I), a preparation method therefor, and the use thereof in preparing pharmaceutical formulations for preventing and / or treating diseases caused by CRBN abnormality. The compounds with the structure shown as formula (I) are small molecule compounds having activity of covalently binding to CRBN so as to inhibit same. The diseases caused by CRBN abnormality are tumors or autoimmune diseases, the tumors including mantle cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma or solid tumors, and the autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis or psoriasis.

Disclosed in the present application are compounds having a benzamide structure as shown in formula (I), a preparation method therefor, and the use thereof in preparing pharmaceutical formulations for preventing and / or treating diseases caused by CRBN abnormality. The compounds with the structure shown as formula (I) are small molecule compounds having activity of covalently binding to CRBN so as to inhibit same. The diseases caused by CRBN abnormality are tumors or autoimmune diseases, the tumors including mantle cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma or solid tumors, and the autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis or psoriasis.

Recombinant receptors with a binding domain that binds B cell activation factor receptor (BAFF-R) are disclosed. Recombinant receptors include chimeric antigen receptors (CAR) having an anti-BAFF-R binding domain, a transmembrane domain, a CD3ζ / 4-1BB intracellular signaling domain, and a spacer. Methods and systems to treat BAFF-R-expressing cancers, such as mantle cell lymphoma (MCL), multiple myeloma (MM), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL), are also provided. The recombinant receptors disclosed herein can bind and elicit cytotoxic effects even in low antigen density conditions.

This invention discloses a compound with BTK inhibitory activity, its preparation method, and its application; the compound is shown in Formula I. The compound of this invention can effectively inhibit Bruton's tyrosine kinase and can be used as a targeted drug for the treatment of diseases related to the BTK signaling pathway, such as chronic lymphocytic leukemia, multiple myeloma, mantle cell lymphoma, systemic lupus erythematosus, rheumatoid arthritis, and chronic graft-versus-host disease.

The invention discloses a compound with BTK inhibitory activity and a preparation method and application thereof. The compound is shown as a formula I. The compound can effectively inhibit Bruton's tyrosine kinase, and can be applied to targeted drugs for treating diseases related to BTK signal channels, such as chronic lymphocytic leukemia, multiple myeloma, mantle cell lymphoma, systemic lupus erythematosus, rheumatic arthritis, chronic graft versus host disease and the like.

Methods are provided for the continuous administration to a subject requiring treatment of a formulation comprising an immunomodulatory imide compound. In some modalities, the method is used for the treatment of multiple myeloma, transfusion-dependent anemia due to low- or intermediate-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.

The application relates to the field of data processing, and discloses a mantle cell lymphoma prognosis evaluation method and system, wherein the method comprises the following steps: acquiring basic diagnosis and treatment data of mantle cell lymphoma of a target patient, performing prognosis evaluation on the target patient based on basic diagnosis and treatment indexes in the basic diagnosis and treatment data to obtain a basic prognosis evaluation score, acquiring index data of a Ki-67 percentage and other special prognosis diagnosis and treatment indexes of the target patient to perform prognosis evaluation on the target patient to obtain a special prognosis evaluation score, and comprehensively evaluating the basic prognosis evaluation score and the special prognosis evaluation score corresponding to the special prognosis diagnosis and treatment indexes to obtain a mantle cell lymphoma prognosis evaluation result of the target patient. The main purpose of the application is to improve the accuracy of mantle cell lymphoma prognosis evaluation.

The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecule is an anti-CD180 antibody. Also provided is an anti-CD180 antibody-drug conjugate (ADC) comprising a monoclonal antibody or antigen-binding fragment thereof that targets CD180-highly expressing tumors, a cytotoxic drug payload, and a linker moiety that conjugates the antibody or antigen-binding fragment thereof that targets CD180-highly expressing tumors to the cytotoxic drug payload. The anti-CD180 antibody or antigen-binding fragment thereof, and the ADC comprising the anti-CD180 antibody or antigen-binding fragment thereof, are useful in treating diseases such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma, follicular lymphoma, acute B-lymphoblastic leukemia, or diffuse large B-cell lymphoma.

According to the application of the anti-CD20 antibody drug conjugate in preparing the drug for treating mantle cell lymphoma, the drug has a good clinical curative effect on treating recurrent or refractory mantle cell lymphoma, is safe and controllable, and meets the clinical requirements which are not met at present.

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Topli) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.

The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecule is an anti-CD180 antibody. Also provided are anti-CD180 antibody-drug conjugates (ADCs) comprising a tumor targeting monoclonal antibody, which highly expresses CD180, or an antigen-binding fragment thereof, a cytotoxic drug payload, and a linker moiety that conjugates the tumor targeting antibody, which highly expresses CD180, or an antigen-binding fragment thereof to the cytotoxic drug payload. The anti-CD180 antibodies or antigen-binding fragments thereof, and the ADCs comprising the anti-CD180 antibodies or antigen-binding fragments thereof, are useful for the treatment of a disease, such as acute myelogenous leukemia, mantle cell lymphoma, multiple myeloma, follicular lymphoma, B-acute lymphoblastic leukemia, or diffuse large B-cell lymphoma.